17 Nov 2015
Gamal Esmat, MD, professor of Hepatology and endemic medicine at Cairo University and WHO viral Hepatitis expert, presented advanced results of the abstract entitled: high virologic response rate in Egyptian HCV-genotype 4 patients treated with Ravidasvir (PPI-668) and Sofosbuvir: results of a large multicenter phase 3 registrational trial.
Dr. Gamal Esmat, representing Pharco, was the first Arab to present at the closing ceremony, where the major treatment protocols for the upcoming years are agreed upon.